title: DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.
abstract: Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Center for Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chalkias
authors.forename: M R
authors.initials: MR
authors.lastname: Mackenzie
authors.forename: C
authors.initials: C
authors.lastname: Gay
authors.forename: C
authors.initials: C
authors.lastname: Dooley
authors.forename: F M
authors.initials: FM
authors.lastname: Marty
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: T
authors.initials: T
authors.lastname: Li
authors.forename: R L
authors.initials: RL
authors.lastname: Routh
authors.forename: S R
authors.initials: SR
authors.lastname: Walsh
authors.forename: C S
authors.initials: CS
authors.lastname: Tan
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018184:Paramyxoviridae Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011024:Pneumonia, Viral / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D020123:Sirolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; C525612:oplunofusp; D011241:Prednisone; D020123:Sirolimus
keywords: DAS181; HSCT; mechanical ventilation; parainfluenza